120.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$123.21
Aprire:
$122.86
Volume 24 ore:
6.83M
Relative Volume:
0.95
Capitalizzazione di mercato:
$149.38B
Reddito:
$29.05B
Utile/perdita netta:
$8.11B
Rapporto P/E:
18.65
EPS:
6.4563
Flusso di cassa netto:
$9.16B
1 W Prestazione:
-0.68%
1M Prestazione:
-2.43%
6M Prestazione:
+7.45%
1 anno Prestazione:
+30.33%
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences Inc
|
120.40 | 152.86B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $151.00 at Morgan Stanley - MarketBeat
Treasurer of the State of North Carolina Has $85.51 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Acquires 140,158 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Benjamin Edwards Inc. - MarketBeat
BlueCrest Capital Management Ltd Buys Shares of 13,553 Gilead Sciences, Inc. $GILD - MarketBeat
AQR Capital Management LLC Has $272.21 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Ameriprise Financial Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead, Arcus scrap late-stage trial of cancer drug combo - 1470 & 100.3 WMBD
Gilead Sciences, Inc. $GILD Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure - BioSpace
GILEAD SCIENCES (GILD): Morgan Stanley Raises Price Target, Main - GuruFocus
Arcus cancels work on Gilead-partnered cancer combo after trial setback - BioPharma Dive
Arcus scraps late-stage cancer trial after weak survival data - Reuters
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com
Morgan Stanley Adjusts PT on Gilead Sciences to $151 From $147, Maintains Overweight Rating - marketscreener.com
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha
Gilead Sciences, Inc. $GILD Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
Sei Investments Co. Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
NewEdge Advisors LLC Has $11.81 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Alliancebernstein L.P. Sells 809,531 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer - Oncodaily
Ex-Dividend Reminder: Gilead Sciences, Merck and Horace Mann Educators - Nasdaq
January 2026 Options Now Available For Gilead Sciences (GILD) - Nasdaq
The Manufacturers Life Insurance Company Sells 95,568 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Who Owns Gilead Sciences? Top Shareholders and Recent Insider Trades - TIKR.com
CIBC Asset Management Inc Sells 28,874 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Wells Fargo Maintains Gilead Sciences (GILD) Overweight Recommendation - Nasdaq
GILD: Wells Fargo Raises Price Target for Gilead Sciences | GILD Stock News - GuruFocus
Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $133.00 at HSBC - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Why You Might Be Interested In Gilead Sciences, Inc. (NASDAQ:GILD) For Its Upcoming Dividend - simplywall.st
Wells Fargo Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating - marketscreener.com
HSBC Adjusts Price Target on Gilead Sciences to $133 From $110, Maintains Hold Rating - marketscreener.com
Here's What We Like About Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend - Yahoo Finance
30,000 Shares in Gilead Sciences, Inc. $GILD Bought by Diadema Partners LP - MarketBeat
Dymon Asia Capital Singapore PTE. LTD. Purchases Shares of 18,000 Gilead Sciences, Inc. $GILD - MarketBeat
Ariel Investments LLC Has $40.90 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Investment Management Corp of Ontario Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Lombard Odier Asset Management Switzerland SA Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
State Street Corp Sells 335,515 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Ossiam Sells 15,066 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Jump Financial LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Three Catalysts Driving Investor Attention Toward Gilead Sciences - AD HOC NEWS
Gilead Sciences, Inc. $GILD Shares Sold by Bank of Nova Scotia - MarketBeat
ASH25: CAR-T Leaders Gilead, J&J Show in Multiple Myeloma; Fulcrum Rises on Sickle Cell Data - BioSpace
WINTON GROUP Ltd Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
ASH: Gilead preps filing for anito-cel on iMMagine-1 data - Pharmaphorum
What Does the Market Think About Gilead Sciences Inc? - Benzinga
Gilead Sciences, Inc. $GILD Shares Bought by Natixis - MarketBeat
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gilead Sciences Inc Azioni (GILD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bluestone Jeffrey | Director |
Nov 28 '25 |
Sale |
125.08 |
5,000 |
625,400 |
8,920 |
| Kramer Kelly A. | Director |
Nov 26 '25 |
Option Exercise |
81.00 |
2,806 |
227,286 |
4,145 |
| Kramer Kelly A. | Director |
Nov 28 '25 |
Option Exercise |
81.00 |
2,805 |
227,205 |
4,144 |
| Kramer Kelly A. | Director |
Nov 26 '25 |
Sale |
127.11 |
2,806 |
356,671 |
1,339 |
| Kramer Kelly A. | Director |
Nov 28 '25 |
Sale |
127.10 |
2,805 |
356,516 |
1,339 |
| O'Day Daniel Patrick | Chairman & CEO |
Nov 28 '25 |
Sale |
126.54 |
10,000 |
1,265,444 |
571,203 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):